Skip to main content
Premium Trial:

Request an Annual Quote

Genentech to Use Horizon for Cancer Studies

NEW YORK (GenomeWeb News) – Horizon Discovery said today that Genentech will use its technology to develop cancer models for drug discovery programs.

The Cambridge, UK-based company said Genentech will be able to use its GENESIS gene-engineering platform to develop genetically defined human cancer models for cancer studies.

These mutant and normal cell lines, called X-MAN, provide a source of human cell-types that hold specific cancer causing genes plus a matched normal cell as a control. This method could enable development of novel drugs or treatments that target specific patient populations, said Horizon.

Horizon said that under the three-year agreement Genentech will pay it an undisclosed, up-front fee, as well as milestones and renewable fees, as it has in previous agreements between the two companies.

Horizon CEO Chris Torrance said the company’s platform enables users to generate a range of disease models that are “difficult or impossible” to generate using other gene-engineering techniques.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.